Slanix Paul Alex
About Slanix Paul Alex
Independent director at ProMIS Neurosciences (PMN) since October 22, 2025; current term runs until the 2026 annual meeting. Background includes President & Portfolio Manager (Public Equity) at Ally Bridge Group since 2023; prior roles across buy-side (Tri Locum Partners, Consonance Capital) and sell-side biotech research (RBC Capital Markets, Credit Suisse), with a Pharm.D. from St. John’s University and pharmacist licensure. The Board determined he is independent under Nasdaq listing standards; he entered into the company’s standard indemnification agreement. Age not disclosed.
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Ally Bridge Group | President & Portfolio Manager, Public Equity | 2023–present | Leads public equity strategy; ABG is a significant PMN shareholder |
| Tri Locum Partners | Founding Partner & Senior Analyst | Prior to 2023 (dates not disclosed) | Life sciences investing |
| Consonance Capital Management | Investment Analyst | Prior to 2023 (dates not disclosed) | Life sciences investing |
| RBC Capital Markets | Sell-side Biotechnology Equity Research | Prior to 2023 (dates not disclosed) | Coverage experience |
| Credit Suisse | Sell-side Biotechnology Equity Research | Prior to 2023 (dates not disclosed) | Coverage experience |
| Bionest Partners | Strategy Consulting (BD/commercial strategy for life sciences) | Career start (dates not disclosed) | Strategic advisory |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Ally Bridge Group | President & Portfolio Manager, Public Equity | 2023–present | ABG affiliate; ABG MedAlpha Master Fund L.P. beneficially owned ~11.26% of PMN as of Sep 17, 2025 |
No other public company directorships for Dr. Alex disclosed in PMN filings.
Board Governance
- Appointment and independence: Appointed Oct 22, 2025; Board determined he is independent under Nasdaq standards. Term through 2026 annual meeting; standard indemnification executed.
- Committees: “Compositions of the Compensation Committee, Nominating Committee and Audit Committee remain unchanged” as of his appointment (i.e., no committee assignment at appointment).
- Attendance/engagement: Not applicable for 2025 post-appointment period; for context, in 2024 PMN’s board held 6 meetings and all directors then in office attended ≥75% of board/committee meetings.
- Shareholder approvals context: Special Meeting on Nov 17, 2025 approved authority for a reverse split and adjournment proposal; quorum ~45.21% present.
Fixed Compensation
| Component | Amount/Terms | Source |
|---|---|---|
| Annual Board Cash Retainer | $40,000 per year (non-employee director) | |
| Committee Chair Fees | Audit: $15,000; Compensation: $10,000; Nominating & Corporate Governance: $8,000 (annual) | |
| Committee Member Fees (non-chair) | Audit: $7,500; Compensation: $5,000; Nominating & Corporate Governance: $4,000 (annual) | |
| Expense Reimbursement | Reasonable out-of-pocket expenses reimbursed |
As of appointment, committees “remain unchanged,” implying no committee fees initially.
Performance Compensation
| Award Type | Grant/Eligibility | Quantity | Vesting | Notes |
|---|---|---|---|---|
| Initial Option Award | Granted on appointment (Oct 22, 2025) | 40,000 | 25% at grant; remaining vests ratably over 36 months (service-based) | Non-statutory option per policy; plan requires ≥FMV exercise price; term ≤10 years (plan general) |
| Annual Option Award | Eligible beginning with 2026 annual meeting | 20,000 | Vests in full on earlier of 1-year from grant or next annual meeting (service-based) | Service-based; not performance-conditioned |
| Change-in-Control/Acceleration | Board may provide full acceleration upon Triggering Event under equity plans (policy-level) | — | — | Policy states potential full acceleration at Board discretion |
Performance metrics: None disclosed for director equity (awards are time-based).
Other Directorships & Interlocks
| Entity | Relationship | Details |
|---|---|---|
| Ally Bridge MedAlpha Master Fund L.P. | Significant shareholder | Beneficial owner of ~6,058,738 common shares; ~11.26% as of Sep 17, 2025; warrants subject to 9.99% blocker; affiliation via Dr. Alex’s ABG role. |
| Related-party/Item 404(a) | None | Company states Dr. Alex is not party to any transaction requiring disclosure under Item 404(a); no selection arrangements disclosed. |
Compensation attribution: Pursuant to ABG governance policy, Dr. Alex’s PMN director equity and cash compensation are attributed to Ally Bridge MedAlpha Master Fund L.P., not to him personally.
Expertise & Qualifications
- Pharm.D., St. John’s University; licensed pharmacist.
- Deep capital markets and life sciences investment expertise (buy-side and sell-side biotech research).
- Strategic/BD advisory experience from Bionest Partners.
Equity Ownership
| Item | Amount/Status | Notes |
|---|---|---|
| Individual beneficial ownership | Not disclosed | Initial equity awards granted at appointment; attribution to ABG fund per policy. |
| Options outstanding (Initial Award) | 40,000 | 25% vested at grant; remainder monthly over 36 months (service-based). |
| Annual option eligibility | 20,000 (starting 2026 AGM) | Vests fully by 1-year or next AGM (service-based). |
| Shares pledged/hedged | None disclosed | — |
| Ownership guidelines (directors) | Not disclosed | — |
| Significant shareholder linkage | ABG MedAlpha ~11.26% | As of Sep 17, 2025. |
Governance Assessment
-
Positives
- Independent status under Nasdaq; no Item 404(a) related-party transactions disclosed; standard indemnification in place.
- Compensation structure aligned with broad PMN director policy (modest cash, equity time-based options), with clear vesting schedules.
- Significant capital markets and biotech expertise likely to support financing and strategy as PMN approaches 2026 trial readouts.
-
Risks/Watch Items
- Potential perceived conflict: director affiliated with a top shareholder (ABG MedAlpha ~11.26%). Mitigants: independence determination, no Item 404(a) transactions, and compensation attributed to ABG rather than personally; monitor for any future related-party interactions, committee assignments (especially Compensation/Audit), or changes in ABG holdings.
- Committee roles/attendance for Dr. Alex not yet established given the late-2025 appointment; track 2026 proxy for attendance and committee assignments.
-
Shareholder confidence signals
- Special Meeting outcomes (reverse split authority) suggest active shareholder engagement; while not directly related to the director, it frames governance context around listing compliance.